Recently, Saiyun Biotechnology (Chengdu) Co., Ltd. (hereinafter referred to as "Saiyun Biotechnology"), a biotechnology company specializing in the development of international cutting-edge delivery carrier technology and innovative drug therapies, announced the completion of tens of millions of angel+round financing. This round of financing is exclusively invested by Zhongke Chuangxing, and the funds raised will mainly be used to accelerate the development process of the company's self-developed pipelines.

Saiyun Biotechnology is an enterprise dedicated to the research and development of targeted delivery technology and innovative drug therapies. It has successfully developed a biomimetic delivery system with independent intellectual property rights, which is different from mainstream delivery carrier systems. After rational transformation, the system can achieve precise cell delivery of various types of payloads, and has significant advantages in specificity recognition, payload compatibility, protection, and production cost.

As an emerging type of delivery system, the research and development progress of "Saiyun Biology" is currently at the forefront of the international community. Previously, the company had received tens of millions of yuan in angel round financing from well-known investment institutions such as Zhongfa Lingchuang/Life Park Venture Capital Fund, IDG Capital, and Innoangel. Saiyun Biotechnology is incubated by Life Park Venture Capital Shared Space and has established a multi technology platform research and development center in Zhongguancun Life Science Park.

Saiyun Biotechnology has a team composed of senior scientists and industry experts, and has established multiple research and development pipelines in the fields of tumor targeted therapy and cell gene therapy. At present, the effectiveness, safety evaluation, and production process optimization of related drug delivery are being carried out in an orderly manner.

Regarding this round of financing, Dr. Jiang Feng, co-founder of "Saiyun Biotechnology", expressed his sincere gratitude to Zhongke Chuangxing for their trust and support. In the field of precision medicine, drug delivery technology has always been a key bottleneck restricting the development of the industry. Currently, both small and large molecule drugs face the challenge of low delivery efficiency, and there is a huge unmet clinical demand in this field. As an innovative enterprise focusing on targeted delivery therapy of biomolecules, "Saiyun Biotechnology" relies on its independently developed new delivery technology platform to explore the forefront of drug delivery and is committed to promoting breakthrough progress in innovative drug research and development in China

Zhongke Chuangxing stated that with the diversification of drug forms, the value of delivery systems is becoming increasingly prominent. CGT、 Nucleic acid ADC、 Popular emerging drug types such as peptide drugs are all developed around the delivery of active drug molecules. The existing delivery systems still have problems in specific cell targeting, escape of inclusions, and types of payloads that are difficult to solve, and there is a large demand for new delivery systems in the industry. The research achievements of Professor Jiang Feng and "Saiyun Biology" have demonstrated tremendous innovation potential, with significant advantages in their core technology platform and research and development pipeline. The angel+round investment in "Saiyun Biotechnology" this time is based on full recognition of its technological strength and market prospects. We believe that through this investment, 'Saiyun Biotechnology' will accelerate the transformation of its technological achievements and bring more benefits to patients worldwide.